Conclusions
adenocarcinoma, PD‐L1
ADENOCARCINOMA
The perioperative pembrolizumab and mFOLFOX combination in resectable esophageal/gastric/GEJ adenocarcinoma is very effective with 90% ypRR, 21% ypCR, and impressive long‐time survival benefits.This phase II study assessed the combination of the immune checkpoint inhibitor, pembrolizumab, and chemotherapy mFLOFOX perioperatively in locally advanced esophageal/gastric/GEJ adenocarcinoma. The results showed impressive results of 90% ypRR, 21% ypCR, and impressive long‐time survival benefits (88.5% of 3 years, DFS of 88.5%, and 3 years OS of 92.3%) with demonstrating perioperative therapy increasing PD‐L1 (CPR ≥10, 
